Glenmark launches acne drug Winlevi in Europe

11 Jun 2026via NSE FilingSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Glenmark launches acne drug Winlevi in Europe — Glenmark Pharmaceuticals has launched Winlevi® (clascoterone) 10 mg/g cream in key European markets for acne vulgaris. The product launch expands its dermatology portfolio in Europe. Winlevi is a first-in-class topical androgen receptor inhibitor. This move strengthens Glenmark’s presence in the European skincare market.

📊 STOCKS: GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #DrugLaunch

#Drug Launch#Europe#Acne Treatment

Stocks mentioned

GLENMARKGLENMARK

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →